Photobiomodulation Therapy for Symptom Management in Essential Palatal Myoclonus: Two Case Studies with Long-Term Follow-Up Two Cases: 7-Year/2-Month Follow-Up.

Photobiomodul Photomed Laser SurgJul 2, 2026 (epub)

Manaf T Agha, Eddie Basson, Pavel Polenik et al.

✦ AI-curated · Sources linked

Case in brief

Two patients with essential palatal myoclonus (PM) underwent photobiomodulation therapy (PBMT) after conventional treatments failed. The first patient, a 26-year-old female, experienced a significant reduction in contraction frequency from 2.5 Hz to 0.11 Hz over 20 sessions, with sustained improvement in swallowing and sleep over 7 years. The second patient, a 28-year-old male, showed a decrease from 3 Hz to 0.3 Hz within 60 days, with notable functional improvement.

Diagnostic / clinical pearl

Photobiomodulation therapy may provide a noninvasive and effective treatment option for essential palatal myoclonus, particularly in cases unresponsive to conventional therapies.

Source

PubMed · PMID 42392993

Published in Photobiomodul Photomed Laser Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegram LinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary

Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary

Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

Your specialties
Your filters and thresholds
Clinical Research + Case Reports, tuned separately
Automatic weekly delivery
Audio and text

Create my personalized digest See plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.